NCT07284615 Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial
| NCT ID | NCT07284615 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ospedale Edoardo Bassini |
| Condition | Arthropathy of Hip |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2026-01-26 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized controlled trial aims to compare two multimodal regional anesthesia strategies for postoperative analgesia in elective total hip arthroplasty (THA) performed via anterior approach. Patients will be randomized to receive either a Pericapsular Nerve Group (PENG) block combined with a Lateral Femoral Cutaneous Nerve (LFCN) block, or a PENG block combined with wound infiltration (WI). The primary outcome is postoperative pain intensity at rest, measured by Numerical Rating Scale (NRS) at 6 hours after surgery. Secondary outcomes include dynamic pain scores at 6, 24, and 48 hours, total opioid consumption, time to first rescue analgesia, quadriceps strength, hip flexion angle, length of stay, and adverse events. All procedures are routinely used in clinical practice and carry minimal additional risk. Safety will be continuously monitored by the Principal Investigator and the study team according to an internal Safety Monitoring Plan.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Elective total hip arthroplasty * Spinal (subarachnoid) anesthesia * Written informed consent provided by the patient or by the legal guardian, if appointed Exclusion Criteria: * INR \> 1.5 * aPTT \> 1.5 * Platelet count \< 75,000/mm³ * Signs suggestive of infection at the puncture site * Absence of informed consent to the procedure * Documented or suspected allergy to local anesthetics
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07284615 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthropathy of Hip. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07284615 currently recruiting?
Yes, NCT07284615 is actively recruiting participants. Contact the research team at matteo.coccolo@asst-nordmilano.it for enrollment information.
Where is the NCT07284615 trial being conducted?
This trial is being conducted at Cinisello Balsamo, Italy.
Who is sponsoring the NCT07284615 clinical trial?
NCT07284615 is sponsored by Ospedale Edoardo Bassini. The trial plans to enroll 102 participants.